首页 | 本学科首页   官方微博 | 高级检索  
     


Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma
Authors:Kitsada Wudhikarn  Udomsak Bunworasate  Jakrawadee Julamanee  Arnuparp Lekhakula  Supachai Ekwattanakit  Archrob Khuhapinant  Pimjai Niparuck  Suporn Chuncharunee  Tontanai Numbenjapon  Kannadit Prayongratana  Nonglak Kanitsap  Somchai Wongkhantee  Nisa Makruasri  Peerapon Wong  Lalita Norasetthada  Weerasak Nawarawong  Chittima Sirijerachai  Kanchana Chansung  Tawatchai Suwanban  Pannee Praditsuktavorn  Tanin Intragumtornchai  
Abstract:
Event free survival at 24 months (EFS24) has been described as a powerful predictor for outcome in several subtypes of B cell lymphoma. However, it was limitedly described in T cell lymphoma. We explored the implication of EFS24 as a predictor marker for peripheral T cell lymphoma (PTCL). We reviewed 293 systemic PTCL patients at 13 nationwide major university hospitals in Thailand from 2007 to 2014. The median event free survival (EFS) and overall survival (OS) of PTCL patients in our cohort was 16.3 and 27.7 months with corresponding 2‐year EFS and 2‐year OS of 45.8% and 51.9%, respectively. A total of 118 patients achieved EFS24 (no events during the first 24 mo). Patients who achieved EFS24 had better OS than patients who did not (2‐y OS 92% vs 18.8%; HR, 0.1; P < .001). The standardized mortality ratio of patients achieving EFS24 was 18.7 (95% CI, 14.6‐22.8). Multivariable analysis demonstrated performance status, histologic subtype, remission status, and EFS24 achievement as independent predictors for OS. Our study affirmed the value of EFS24 as a powerful prognostic factor for PTCL. Further validation in prospective study setting is warranted.
Keywords:EFS24  event free survival  peripheral T cell lymphoma  prognosis  risk stratification
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号